167 related articles for article (PubMed ID: 38518928)
1. Fused thiophene as a privileged scaffold: A review on anti-Alzheimer's disease potentials via targeting cholinesterases, monoamine oxidases, glycogen synthase kinase-3, and Aβ aggregation.
Kassab AE; Gedawy EM; Sayed AS
Int J Biol Macromol; 2024 Apr; 265(Pt 2):131018. PubMed ID: 38518928
[TBL] [Abstract][Full Text] [Related]
2. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
Mazumder MK; Choudhury S
Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
[TBL] [Abstract][Full Text] [Related]
3. The neurobiology and therapeutic potential of multi-targeting β-secretase, glycogen synthase kinase 3β and acetylcholinesterase in Alzheimer's disease.
Fronza MG; Alves D; Praticò D; Savegnago L
Ageing Res Rev; 2023 Sep; 90():102033. PubMed ID: 37595640
[TBL] [Abstract][Full Text] [Related]
4. Progress in Target Drug Molecules for Alzheimer's Disease.
Xie J; Liang R; Wang Y; Huang J; Cao X; Niu B
Curr Top Med Chem; 2020; 20(1):4-36. PubMed ID: 31797761
[TBL] [Abstract][Full Text] [Related]
5. Identification of Butyrylcholinesterase and Monoamine Oxidase B Targeted Ligands and their Putative Application in Alzheimer's Treatment: A Computational Strategy.
Jabir NR; Rehman MT; Tabrez S; Alserihi RF; AlAjmi MF; Khan MS; Husain FM; Ahmed BA
Curr Pharm Des; 2021; 27(20):2425-2434. PubMed ID: 33634754
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.
Barai P; Raval N; Acharya S; Borisa A; Bhatt H; Acharya N
Behav Brain Res; 2019 Jan; 356():18-40. PubMed ID: 30118774
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic implications of glycogen synthase kinase-3β in Alzheimer's disease: a novel therapeutic target.
Mandlik DS; Mandlik SK; S A
Int J Neurosci; 2024 Jun; 134(6):603-619. PubMed ID: 36178363
[TBL] [Abstract][Full Text] [Related]
8. N-alkylpiperidine carbamates as potential anti-Alzheimer's agents.
Košak U; Strašek N; Knez D; Jukič M; Žakelj S; Zahirović A; Pišlar A; Brazzolotto X; Nachon F; Kos J; Gobec S
Eur J Med Chem; 2020 Jul; 197():112282. PubMed ID: 32380361
[TBL] [Abstract][Full Text] [Related]
9. Phenyl-quinoline derivatives as lead structure of cholinesterase inhibitors with potency to reduce the GSK-3β level targeting Alzheimer's disease.
Noori M; Dastyafteh N; Safapoor S; Khalili Ghomi M; Tanideh R; Zomorodian K; Hamedifar H; Dara M; Zare S; Irajie C; Javanshir S; Rastegar H; Panahi N; Larijani B; Mahdavi M; Hajimiri MH; Iraji A
Int J Biol Macromol; 2023 Dec; 253(Pt 7):127392. PubMed ID: 37827412
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in the Development of Nitrogen-containing Heterocyclic Anti-alzheimer's Agents.
Kumar A; Nehra B; Singh D; Kumar D; Chawla PA
Curr Top Med Chem; 2023; 23(13):1277-1306. PubMed ID: 36278462
[TBL] [Abstract][Full Text] [Related]
11. Effect of amyloid-β (Aβ) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3β.
Amin J; Paquet C; Baker A; Asuni AA; Love S; Holmes C; Hugon J; Nicoll JA; Boche D
Neuropathol Appl Neurobiol; 2015 Jun; 41(4):445-57. PubMed ID: 25486988
[TBL] [Abstract][Full Text] [Related]
12. TV 3326 for Alzheimer's dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer's-like neuropathology.
Uddin MS; Kabir MT; Rahman MM; Mathew B; Shah MA; Ashraf GM
J Pharm Pharmacol; 2020 Aug; 72(8):1001-1012. PubMed ID: 32149402
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.
León R; Garcia AG; Marco-Contelles J
Med Res Rev; 2013 Jan; 33(1):139-89. PubMed ID: 21793014
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic Insight into the Design of Chemical Tools to Control Multiple Pathogenic Features in Alzheimer's Disease.
Han J; Du Z; Lim MH
Acc Chem Res; 2021 Oct; 54(20):3930-3940. PubMed ID: 34606227
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
Liu W; Liu X; Liu W; Gao Y; Wu L; Huang Y; Chen H; Li D; Zhou L; Wang N; Xu Z; Jiang X; Zhao Q
Eur J Med Chem; 2022 Feb; 229():114095. PubMed ID: 34995924
[TBL] [Abstract][Full Text] [Related]
16. Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus.
Hamodat H; Cash MK; Fisk JD; Darvesh S
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):571-583. PubMed ID: 28644906
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic and urinary metabolomics studies on the mechanism of Schisandra polysaccharide in the treatment of Alzheimer's disease.
Liu Y; Liu Z; Wei M; Hu M; Yue K; Bi R; Zhai S; Pi Z; Song F; Liu Z
Food Funct; 2019 Jan; 10(1):432-447. PubMed ID: 30623955
[TBL] [Abstract][Full Text] [Related]
18. Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway.
Reale M; Di Nicola M; Velluto L; D'Angelo C; Costantini E; Lahiri DK; Kamal MA; Yu QS; Greig NH
Curr Alzheimer Res; 2014; 11(6):608-22. PubMed ID: 24359497
[TBL] [Abstract][Full Text] [Related]
19. Diabetes mellitus and Alzheimer's disease: GSK-3β as a potential link.
Zhang Y; Huang NQ; Yan F; Jin H; Zhou SY; Shi JS; Jin F
Behav Brain Res; 2018 Feb; 339():57-65. PubMed ID: 29158110
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase-3 signaling in Alzheimer's disease.
Lauretti E; Dincer O; Praticò D
Biochim Biophys Acta Mol Cell Res; 2020 May; 1867(5):118664. PubMed ID: 32006534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
